Replimune Group, Inc. — Director's Dealing 2020

Sep 1, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Replimune Group, Inc. (REPL)
CIK: 0001737953
Period of Report: 2020-08-31

Reporting Person: Esposito Pamela (Chief Business Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-08-31	Common Stock	M	5000	$1.01	Acquired	117700	Direct
2020-08-31	Common Stock	S	5000	$27.05	Disposed	112700	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-08-31	Employee Stock Option (right to buy)	$1.01	M	5000	Disposed	2025-11-01	Common Stock (5000)	Direct

Footnotes

F1: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on June 15, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.

F2: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.18.

F3: Following the sales reported on this Form 4, the reporting person continues to beneficially own 112,700 shares of the Issuer's common stock. The reporting person also holds options to acquire an aggregate of 593,146 shares of the Issuer's common stock, 394,440 of which are exercisable as of the date hereof.

F4: The reporting person was granted an option to purchase 149,203 shares of the Issuer's common stock on November 1, 2015. All of the shares underlying the stock option have vested and are exercisable as of the date hereof.